Osteoblastic metastatic disease as a therapeutic response to adjuvant chemotherapy in breast cancer

✍ Scribed by Angela L. Demartini; Aman U. Buzdar; George R. Blumenschein

• Publisher: John Wiley and Sons
• Year: 1983
• Tongue: English
• Weight: 262 KB
• Volume: 23
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930230109

✦ Synopsis

Included in this study were 43 breast cancer patients treated with adjuvant chemotherapy who presented metastasis only in bone. Forty-two percent had metastasis during chemotherapy, and 58% had metastasis after the completion of chemotherapy. In 66% of the patients, the lesions were osteolytic. Twenty-nine percent had osteoblastic lesions, and 5 % had mixed lesions. Of the patients with osteoblastic metastatic disease, five showed asymptomatic, osteoblastic disease; this response was considered to be a healing response to chemotherapy. These five patients were continued on the same therapy. The median duration of this response to the adjuvant chemotherapy was 29 months (range 6 to 62+). In one patient, osteoblastic disease gradually faded, and skeletal radiographs reverted to normal.